Sangmin Yong

Sangmin Yong

Auto-generated profile, based on publicly available information

Sangmin Yong

Center for RNA Research, Institute for Basic Science, Seoul, South Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2022 in Science Advances
Verified
Journal Article
Open access
HSHee Su Sohn
Hee Su Sohn
JCJeong Won Choi
Jeong Won Choi
JJJooYeon Jhun
JooYeon Jhun
SKSung Pil Kwon
Sung Pil Kwon
MJMungyo Jung
Mungyo Jung
BKByung-Soo Kim
Byung-Soo Kim
Local inflammation in the joint is considered to contribute to osteoarthritis (OA) progression. Here, we describe an immunomodulating nanoparticle for OA treatment. Intradermal injection of lipid nanoparticles (LNPs) loaded with type II collagen (Col II) and rapamycin (LNP-Col II-R) into OA mice effectively induced Col II–specific anti-inflammatory regulatory T cells, substantially increased anti-inflammatory cytokine expression, and reduced inflammatory immune cells and proinflammatory cytokine expression in the joints. Consequently, LNP-Col II-R injection inhibited chondrocyte apoptosis and cartilage matrix degradation and relieved pain, while injection of LNPs loaded with a control peptide and rapamycin did not induce these events. Adoptive transfer of CD4 + CD25 + T cells isolated from LNP-Col II-R–injected mice suggested that T regs induced by LNP-Col II-R injection were likely responsible for the therapeutic effects. Collectively, this study suggests nanoparticle-mediated immunomodulation in the joint as a simple and effective treatment for OA.

15 September 2026 in Osteoarthritis and Cartilage
Verified
Journal Article
Open access
SCSeoyeon Cho
Seoyeon Cho
SYSangmin Yong
Sangmin Yong
EHEunhee Ha
Eunhee Ha
JKJin-Hong Kim
Jin-Hong Kim
YKYi-Jun Kim
Yi-Jun Kim

30 September 2026 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
YCYongsik Cho
Yongsik Cho
SLSeung Hyun Lee
Seung Hyun Lee
YCYeongrae Cho
Yeongrae Cho
SYSangmin Yong
Sangmin Yong
SKSoy Kim
Soy Kim
JKJin-Hong Kim
Jin-Hong Kim
Background: Osteoarthritis (OA) is a prevalent degenerative joint disease lacking approved disease-modifying therapies. A key pathogenic driver is a senescence-induced microRNA, miR-204-5p, which suppresses glycosaminoglycan-rich proteoglycan anabolism in chondrocytes, thereby driving chondrocytes toward a catabolic state that progressively degrades cartilage. This study aimed to evaluate LF-ASO-001, a chemically optimized antisense oligonucleotide designed to potently degrade miR-204-5p, as a potential disease-modifying therapy for OA. Methods: The structural mechanism of LF-ASO-001 was characterized through molecular docking and molecular dynamics simulations of the Argonaute2 (AGO2)-miR-204-5p complex. To validate its functional activity, we utilized primary murine chondrocytes under stress-induced senescence and miR-204-overexpressing human chondrocytes to assess the restoration of anabolic homeostasis. In vivo pharmacokinetics and safety were profiled via fluorescence-based biodistribution assays and comprehensive toxicity studies. Therapeutic efficacy was evaluated in the murine destabilization of the medial meniscus model. The study design included both an early intervention strategy to assess the prevention of disease progression and a delayed treatment regimen to evaluate the modulation of established pathology following intra-articular administration. Results: Molecular dynamics simulations revealed that LF-ASO-001 displaces the 3’ end of miR-204-5p from the AGO2 PAZ (Piwi-Argonaute-Zwille) domain, destabilizing the miRNA-loaded complex. LF-ASO-001 suppressed senescence-associated inflammatory and matrix-remodeling phenotypes while restoring anabolic gene expression in senescent chondrocytes. A single intra-articular injection achieved durable cartilage retention and robust efficacy in a post-traumatic OA model in mice. LF-ASO-001 not only prevented joint degeneration but also mitigated established disease in a delayed-treatment model, restoring weight-bearing function. In comparative efficacy studies, LF-ASO-001 provided more robust structural protection than a clinical-stage small-molecule candidate and matched the analgesic benefit of dexamethasone. LF-ASO-001 demonstrated a favorable safety profile, showing no local joint toxicity, adverse effects on serum clinical biochemistry, or alterations in subchondral bone architecture. Conclusions: LF-ASO-001 is a promising disease-modifying OA drug candidate that couples durable single-dose pharmacology with joint preservation and symptomatic relief through targeted degradation of miR-204-5p via AGO2 complex destabilization.